Xillix Technologies Corp.
TSX : XLX

Xillix Technologies Corp.

November 15, 2005 10:31 ET

Xillix Signs Australian Distribution Agreement with ConMed Linvatec

RICHMOND, BRITISH COLUMBIA--(CCNMatthews - Nov. 15, 2005) - Xillix Technologies Corp. (TSX:XLX), a world leader in fluorescence endoscopy for the early detection of cancer, today announced that it has entered into a distribution agreement with ConMed Linvatec Australia, a division of ConMed Corporation (NASDAQ:CNMD), and a recognised technological leader in the pulmonary and gastrointestinal (GI) endoscopy market. This agreement appoints ConMed Linvatec as sole distributor of Xillix's latest product, Onco-LIFE™ in Australia for both lung cancer and GI application. An application to market Onco-LIFE has been submitted to the Australian Therapeutic Goods Administration (TGA). The distribution agreement extends to December 2008.

"This Australian distribution agreement follows similar agreements we have with ConMed in North America, which became effective upon U.S. Food and Drug Administration (FDA) approval," said Cynthia Roney, President and CEO of Xillix. "We believe that ConMed Linvatec is an ideal partner in Australia with its dedicated, professional endoscopy sales force and a complementary product line of single-use medical devices used by pulmonary and GI physicians to diagnose and treat diseases using minimally invasive endoscopic techniques."

Xillix VP Sales and Marketing, Patrick du Monceaux, was recently in Australia attending the Australia Gastoenterology Week with ConMed Linvatec and provided Onco-LIFE sales training to the ConMed Linvatec team. "Having ConMed Linvatec as our Australian distribution partner will help introduce a key early cancer detection technology to clinicians in Australia. ConMed Linvatec has a wide breadth of experience and coverage in Australia, and we look forward to working together on this exciting opportunity," said Patrick du Monceaux.

About ConMed Linvatec

The ConMed Corporation acquired Linvatec at the end of December 1997. The company name in Australia was officially changed to ConMed Linvatec in February 2005. The name Linvatec is an acronym for Least Invasive Technologies. For more than 40 years the company has focused it's R&D efforts towards driving the techniques and developing the devices which have seen minimal access surgery become the preferred approach for many of the surgical procedures performed today. It's products serve the clinical areas of sports medicine-arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring, endosurgery and endoscopic technologies. Surgeons and physicians in a variety of specialties including orthopaedics, general surgery, gynaecology, neurosurgery and gastroenterology use ConMed's medical devices. Headquartered in Utica, New York, ConMed's 3,100 employees distribute its products worldwide from eleven manufacturing locations. More information about ConMed is available at www.conmed.com

About Xillix

Xillix Technologies Corp. is a Canadian medical device company and the world leader in fluorescence endoscopy for improved cancer detection. Xillix's latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers. An international multicenter lung cancer clinical trial of Onco-LIFE demonstrated a 325% per-lesion improvement in the detection of early lung cancer (moderate-severe dysplasia and carcinoma in situ) and a 250% per-patient improvement compared to white-light alone. Onco-LIFE is approved for sale in the United States for the lung application and in Europe and Canada for both lung and GI applications. Onco-LIFE is compact, user-friendly and is compatible with a wide range of endoscopes and endoscopic accessories to help maximize global market acceptance.

Note: Certain of the statements contained in this press release contain forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The Company does not expect to update forward-looking statements continually as conditions change. Investors are referred to the full discussion of risk factors associated with the Company's business contained in the Company's Annual Information Form filed with securities regulatory authorities dated March 31, 2005.

The Company is listed on the Toronto Stock Exchange under the trading symbol "XLX".

Contact Information